amino acid sequence is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-26. Numbers and descriptions here follow the published literature rather than marketing material.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
It is disputed whether umami is truly an independent taste because standalone glutamate without table salt ions (Na+) is perceived as sour; sweet and umami tastes share a taste receptor subunit, with salty taste blockers reducing discrimination between monosodium glutamate and sucrose; and some people cannot distinguish umami from a salty taste. Monosodium L-aspartate has an umami taste about a quarter as intense as MSG, whereas ibotenic acid and tricholomic acid (likely as their salts or with salt) are claimed to be many times more intense. Peptides can also generate an umami taste, with 52 of them being known to do so as of 2017 (although 20 of them are contested).
Root canals presenting an oval cross-section are found in 50–70% of root canals. In addition, canals with a "tear-shaped" cross section are common when a single root contains two canals (as occurs, for example, with the additional mesial root seen with the lower molars), subtleties that can be more difficult to appreciate on classical radiographs. Recent studies have shown that use of cone-down CT scans can detect accessory canals that would have been missed in 23% of cases, which can in turn lead to apical periodontitis. The upper molars, in particular, are predisposed to have an occult accessory canal in nearly half of patients.
==== Determining hydrogen storage capacity ==== Two hydrogen-uptake measurement methods are used for the characterization of MOFs as hydrogen storage materials: gravimetric and volumetric. To obtain the total amount of hydrogen in the MOF, both the amount of hydrogen absorbed on its surface and the amount of hydrogen residing in its pores should be considered. To calculate the absolute absorbed amount (Nabs), the surface excess amount (Nex) is added to the product of the bulk density of hydrogen (ρbulk) and the pore volume of the MOF (Vpore), as shown in the following equation:
== Disease causation == Changes in DNA caused by mutation in a coding region of DNA can cause errors in protein sequence that may result in partially or completely non-functional proteins. Each cell, in order to function correctly, depends on thousands of proteins to function in the right places at the right times. When a mutation alters a protein that plays a critical role in the body, a medical condition can result. One study on the comparison of genes between different species of Drosophila suggests that if a mutation does change a protein, the mutation will most likely be harmful, with an estimated 70 per cent of amino acid polymorphisms having damaging effects, and the remainder being either neutral or weakly beneficial. Some mutations alter a gene's DNA base sequence but do not change the protein made by the gene. Studies have shown that only 7% of point mutations in noncoding DNA of yeast are deleterious and 12% in coding DNA are deleterious. The rest of the mutations are either neutral or slightly beneficial.
=== Bibliography === Aerei da combattimento della Seconda Guerra Mondiale (in Italian). Novara, Italy: De Agostini Editore, 2005. Anderson, Peter N. Mustangs of the RAAF and RNZAF. Sydney, Australia: A.H. & A.W. Reed Pty Ltd, 1975. ISBN 0-589-07130-0. Angelucci, Enzo and Peter Bowers. The American Fighter: The Definitive Guide to American Fighter Aircraft from 1917 to the Present. New York: Orion Books, 1985. ISBN 0-517-56588-9. Aro, Chuck and Colin Aro. "World's Fastest Mustangs". Air Enthusiast. No. 13, August–November 1980. pp. 56–62. ISSN 0143-5450 Birch, David. Rolls-Royce and the Mustang. Derby, UK: Rolls-Royce Heritage Trust, 1987. ISBN 0-9511710-0-3. Bowen, Ezra. Knights of the Air (Epic of Flight). New York: Time-Life Books, 1980. ISBN 0-8094-3252-8. Borth, Christy. Masters of Mass Production. Indianapolis, Indiana: Bobbs-Merrill Co., 1945. Bowman, Martin W. P-51 Mustang vs Fw 190: Europe 1943–45. Oxford, UK: Osprey Publishing, 2007. ISBN 1-84603-189-3. Boylan, Bernard. Development of the Long Range Escort Fighter. Washington, D.C.: USAF Historical Division, Research Studies Institute, Air University, 1955. Retrieved: 15 July 2014. Boyne, Walter J. Clash of Wings. New York: Simon & Schuster, 1994. ISBN 0-684-83915-6. Breffort, Dominique with André Jouineau. Le North-American P-51 Mustang – de 1940 à 1980 (Avions et Pilotes 5)(in French). Paris: Histoire et Collections, 2003. ISBN 2-913903-80-0. Bridgman, Leonard, ed. "The North American Mustang." Jane's Fighting Aircraft of World War II. London: Studio, 1946. ISBN 1-85170-493-0.
Sources: en.wikipedia.org
Adding 60 seconds to this invasive procedure, Kahneman found participants reported the colonoscopy as more pleasant. This was attributed to making sure the colonoscopy instrument was not moved during the extra 60 seconds – movement is the source of the most discomfort. Thus, Kahneman was appealing to the remembering self's tendency to focus on the end of the experience. Such findings help explain human error in affective forecasting – people's ability to predict their future emotional states.
==== Dopamine synthesis enhancement ==== Although it is frequently labeled as a stimulant, bromantane is distinct in its pharmacology and effects relative to typical stimulants, such as the phenethylamines (e.g., amphetamine and its derivatives) and their structural analogues (e.g., methylphenidate, cocaine, mesocarb, etc.). Whereas the latter directly act on the dopamine transporter (DAT) to inhibit the reuptake and/or induce the release of dopamine, bromantane instead acts via indirect genomic mechanisms to produce a rapid, pronounced, and long-lasting upregulation in a variety of brain regions of the expression of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD) (also known as DOPA decarboxylase), key enzymes in the dopamine biosynthesis pathway. For instance, a single dose of bromantane produces a 2–2.5 fold increase in TH expression in the rat hypothalamus 1.5–2 hours post-administration. The biosynthesis and release of dopamine subsequently increase in close correlation with TH and AAAD upregulation. Enhancement of dopaminergic neurotransmission is observed in the hypothalamus, striatum, ventral tegmental area, nucleus accumbens, and other regions. As such, the key mechanism of the pharmacological activity and psychostimulant effects of bromantane is activation of the de novo synthesis of dopamine via modulation of gene expression. A selection of quoted excerpts from the medical literature detail the differences between bromantane and typical stimulants:
== External links == Overview of all the structural information available in the PDB for UniProt: P04278 (Sex hormone-binding globulin) at the PDBe-KB. Androgen-Binding+Protein at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Ensembl Gene ref Protein ref
In the European Union, a biological medicinal product is one of the active substance(s) produced from or extracted from a biological (living) system, and requires, in addition to physicochemical testing, biological testing for full characterisation. The characterisation of a biological medicinal product is a combination of testing the active substance and the final medicinal product together with the production process and its control. For example: Production process – it can be derived from biotechnology or from other technologies. It may be prepared using more conventional techniques as is the case for blood or plasma-derived products and a number of vaccines. Active substance – consisting of entire microorganisms, mammalian cells, nucleic acids, proteinaceous, or polysaccharide components originating from a microbial, animal, human, or plant source. Mode of action – therapeutic and immunological medicinal products, gene transfer materials, or cell therapy materials.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.